whose disease has progressed following two or more anti-leukaemia therapies. The drug received accelerated approval from the FDA in 2012 and in 2013 Sprectrum launched Marqibo through its existing haematology sales force. Tekmira is entitled to royalty payments based on the drug's commercial sales. Alnyl